公司問答丨沃森生物:13價肺炎球菌結合疫苗在孟加拉國完成了本地化產品註冊
格隆匯6月10日丨有投資者在互動平台向沃森生物公司提問:公司國際化的進度倒底如何了?孟加拉完成註冊半年了,公司13價進入孟加拉的進展又如何?其他國家又怎麼樣了?公司能不能真誠的吿知投資者?股價持續下跌雖然可以歸結為市場原因,但是公司也應該及時解釋發展前景,否則,不聞不問,只會讓公司信譽受損!沃森生物迴應:13價肺炎球菌結合疫苗在孟加拉國完成了本地化產品註冊,相關工作正在逐步按計劃推進中;公司國際營銷團隊正在與多個意向國家接觸,並同步開展部分目標國家的註冊准入工作,擬通過多樣化的合作方式加快實施公司海外佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.